Alaunos Therapeutics, Inc.
TCRT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001107421
No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Alaunos Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 110 | 102 | −8 |
| Shares | 70.9M | 67.2M | −3.77M (−5.3%) |
| Value | $44.7M | $34.2M | −$10.4M (−23.3%) |
New holders (5)
Institutions that held Alaunos Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Charles Schwab Investment Management Inc | 110,297 | $56.3K | 0.00% |
| Cubist Systematic Strategies, LLC | 41,257 | $21.0K | 0.00% |
| Summit Trail Advisors, LLC | 25,378 | $12.9K | 0.00% |
| Change Path, LLC | 14,800 | $8.00K | 0.00% |
| Rhumbline Advisers | 6,366 | $3.25K | 0.00% |
Sold out (13)
Institutions that held Alaunos Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Jacobs Levy Equity Management, Inc | 1,077,215 | $678.6K |
| Magnolia Capital Advisors LLC | 448,469 | $282.5K |
| Caxton Associates LP | 286,287 | $180.4K |
| Squarepoint Ops LLC | 106,642 | $67.2K |
| Belvedere Trading LLC | 14,795 | $9.32K |
| Magnus Financial Group LLC | 11,000 | $6.93K |
| Pasadena Private Wealth, LLC | 10,596 | $6.67K |
| Byrne Asset Management LLC | 4,035 | $3.00K |
| Psagot Value Holdings Ltd. / (Israel) | 5,115 | $3.00K |
| Equitec Proprietary Markets, LLC | 1,023 | $644 |
| TCI Wealth Advisors, Inc. | 700 | $441 |
| Schubert & Co | 229 | $145 |
| IFP Advisors, Inc | 7,738 | – |